Bank of Nova Scotia
JAZZ icon

Bank of Nova Scotia’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bank of Nova Scotia’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$351K Buy
+1,455
New +$319K ﹤0.01% 1011
2026
Q1 		– Sell
-86,200
Closed -$14.7M – 1151
2025
Q4 		$14.7M Buy
+86,200
New +$13.2M 0.02% 400
2024
Q4 		– Sell
-3,329
Closed -$371K – 1087
2024
Q3 		$371K Sell
3,329
-18,771
-85% -$2.06M ﹤0.01% 891
2024
Q2 		$2.36M Sell
22,100
-24,913
-53% -$2.74M ﹤0.01% 603
2024
Q1 		$5.66M Buy
47,013
+35,860
+322% +$4.39M 0.01% 487
2023
Q4 		$1.37M Buy
11,153
+9,478
+566% +$1.18M ﹤0.01% 719
2023
Q3 		$217K Sell
1,675
-4,497
-73% -$599K ﹤0.01% 944
2023
Q2 		$765K Buy
6,172
+614
+11% +$82.6K ﹤0.01% 711
2023
Q1 		$813K Buy
5,558
+1,524
+38% +$225K ﹤0.01% 749
2022
Q4 		$643K Sell
4,034
-222,787
-98% -$32.7M ﹤0.01% 877
2022
Q3 		$30.2M Buy
226,821
+95,769
+73% +$14.6M 0.1% 173
2022
Q2 		$20.4M Buy
131,052
+96,728
+282% +$14.9M 0.05% 271
2022
Q1 		$5.34M Sell
34,324
-26,366
-43% -$3.83M 0.01% 578
2021
Q4 		$7.73M Buy
+60,690
New +$7.98M 0.01% 599
2020
Q3 		– Sell
-125,998
Closed -$13.9M – 1037
2020
Q2 		$13.9M Buy
+125,998
New +$13.9M 0.05% 258
2020
Q1 		– Sell
-19,000
Closed -$2.84M – 937
2019
Q4 		$2.84M Buy
+19,000
New +$2.59M 0.01% 630
2019
Q3 		– Sell
-23,064
Closed -$3.29M – 921
2019
Q2 		$3.29M Buy
23,064
+64
+0.3% +$8.6K 0.01% 506
2019
Q1 		$3.29M Buy
+23,000
New +$3M 0.01% 526
2018
Q4 		– Sell
-13,000
Closed -$2.19M – 885
2018
Q3 		$2.19M Buy
+13,000
New +$2.24M 0.01% 627
2016
Q4 		– Sell
-15,000
Closed -$1.82M – 843
2016
Q3 		$1.82M Buy
+15,000
New +$2.02M 0.01% 326

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Bank of Nova Scotia's JAZZ Position: Q2 2026 in Review

Bank of Nova Scotia opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 1,455 shares worth $351K. The stake represents ﹤0.01% of the portfolio and ranks #1011 among its holdings. This is a return to the name: Bank of Nova Scotia previously reported a position in JAZZ as recently as Q4 2025.

Bank of Nova Scotia first reported a position in JAZZ in Q3 2016 and has held it in 20 quarters since. The position peaked at $30.2M in Q3 2022. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Bank of Nova Scotia held 1,455 shares of Jazz Pharmaceuticals worth $351K as of Q2 2026.
  • Jazz Pharmaceuticals was a new Bank of Nova Scotia position in Q2 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Bank of Nova Scotia's portfolio in Q2 2026, its #1011 holding.
  • Bank of Nova Scotia first reported a position in Jazz Pharmaceuticals in Q3 2016 and has held it in 20 quarters since.
  • Bank of Nova Scotia's Jazz Pharmaceuticals position peaked at $30.2M in Q3 2022.
  • 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Bank of Nova Scotia's 13F filing for Q2 2026, filed 12 Aug 2026.